A Phase Ib Multiple Ascending Dose Study of BMS-833923 Alone or in Combination With Lenalidomide (Revlimid) Plus Dexamethasone or in Combination With Bortezomib (Velcade) in Subjects With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2012
At a glance
- Drugs BMS 833923; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 31 Dec 2011 Primary endpoint identified as (recommended phase II dose) as reported by ClinicalTrials.gov.
- 29 Sep 2011 Planned end date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.